Sign in
CompletedNo phase

Reducing Antimicrobial Overuse Through Targeted Therapy for Patients With Community-Acquired Pneumonia

Key facts

Who runs it
The Cleveland Clinic
Where
Akron, Avon, Cleveland, Euclid, Fairview Park, Garfield Heights, Mayfield Heights, Medina, Vero Beach, Warrensville Heights, and Weston, United StatesSee the 12 sites
Trial code
Status
Completed
People taking part
28,580 people enrolled
Started
1 Nov 2022
Ended
30 Jun 2026
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Rapid Diagnostic Testing
  • Pharmacist-led de-escalation
Record updated
1 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Men or women greater than or equal to 18 years of age
  • Admitted to a participating (i.e. enrolled and randomized) hospital
  • Admitting diagnosis of pneumonia

Who cannot take part

  • Patients not eligible for empiric therapy due to a known pathogen (any positive blood or respiratory cultures in the 72 hours prior to admission)
  • Admission to intensive care unit within 24 hours of hospital admission
  • Comfort care measures only
  • Cystic fibrosis
  • Discharged from an acute care hospital in the past week

Where in United States

  • Akron General HospitalAkron, United States
  • Avon HospitalAvon, United States
  • Cleveland Clinic - Main CampusCleveland, United States
  • Lutheran HospitalCleveland, United States
  • Euclid HospitalEuclid, United States
  • Fairview HospitalFairview Park, United States
  • Marymount HospitalGarfield Heights, United States
  • Hillcrest HospitalMayfield Heights, United States
  • Medina HospitalMedina, United States
  • Indian River HospitalVero Beach, United States
  • South Pointe HospitalWarrensville Heights, United States
  • Weston Hospital - Cleveland Clinic FloridaWeston, United States

About the trial

What the trial wants to find out

The purpose of this study is to reduce the exposure of broad-spectrum antimicrobials by optimizing the rapid detection of CAP pathogens and improving rates of de-escalation following negative cultures. To accomplish this, we will perform a 3-year, pragmatic, multicenter 2 X 2 factorial cluster randomized controlled trial with four arms: a) rapid diagnostic testing b) pharmacist-led de-escalation c) rapid diagnostic testing + pharmacist-led de-escalation and d) usual care

The 4 groups in the trial

  • Rapid diagnostic testing (RDT)Existing treatment, for comparison

    Rapid diagnostic testing: Eligible patients at hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT and procalcitonin testing. If the patient is not being admitted to the ICU, and the patient has an admitting diagnosis of pneumonia, the form will append orders for viral testing, UAT and procalcitonin testing to providers in hospitals randomized to receive it.

    Treatment: Rapid Diagnostic Testing

  • Pharmacist-led de-escalationExisting treatment, for comparison

    Pharmacist-led de-escalation: Another CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for \> 48 hours and generate a list for the clinical pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily on weekdays at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. The validated measures of clinical stability in patients with CAP are a) resolved vital sign abnormalities b) normal mental status c) ability to eat. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page.

  • Rapid diagnostic testing (RDT) and Pharmacist-led de-escalationExisting treatment, for comparison

    Rapid diagnostic testing: Eligible patients at hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT and procalcitonin testing. If the patient is not being admitted to the ICU, and the patient has an admitting diagnosis of pneumonia, the form will append orders for viral, UAT and procalcitonin testing to providers in hospitals randomized to receive it. Pharmacist-led de-escalation: Another CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for \>48-hours and generate a list for the clinical pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily on weekdays at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page.

    Treatment: Rapid Diagnostic Testing and Pharmacist-led de-escalation

  • Usual care (no intervention)No study treatment, for comparison

    Usual care

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
1 July 2026